Market revenue in 2023 | USD 6,321.8 million |
Market revenue in 2030 | USD 14,279.5 million |
Growth rate | 12.3% (CAGR from 2023 to 2030) |
Largest segment | Growth hormone deficiency |
Fastest growing segment | Growth Hormone Deficiency |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Other Applications, Growth Hormone Deficiency |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to human growth hormone market will help companies and investors design strategic landscapes.
growth hormone deficiency was the largest segment with a revenue share of 48.93% in 2023. Horizon Databook has segmented the Global human growth hormone market based on turner syndrome, idiopathic short stature, prader-willi syndrome, small for gestational age, other applications, growth hormone deficiency covering the revenue growth of each sub-segment from 2018 to 2030.
Robust product pipeline and extensive R&D investments for the development of novel growth hormone therapies are expected to be major factors driving the market growth over the forecast period. In September 2018, Novo Nordisk presented Phase II clinical trial data of its investigational growth hormone therapy, Somapacitan, indicated for the treatment of pediatric growth hormone deficiency. In May 2019, Ascendis Pharma A/S published results from the Phase III clinical trial of its Trans Con Growth Hormone (hGH), indicated for the pediatric growth hormone deficiency.
Similar, various key players including Teva Pharmaceutical Industries, Ltd., OPKO Health, Inc., Eli Lilly and Company, Ferring Pharmaceuticals, Sanofi S.A. and LG Life Sciences are involved in R&D activities for the development of novel human growth hormone therapies.
Horizon Databook provides a detailed overview of global-level data and insights on the Global human growth hormone market , including forecasts for subscribers. This global databook contains high-level insights into Global human growth hormone market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account